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Abstract
Evidence on the use and efficacy of medical cannabis for children is limited. We examined clinical and epidemiological 
characteristics of medical cannabis treatment and caregiver-reported effects in children and adolescents in Switzerland. We 
collected clinical data from children and adolescents (< 18 years) who received Δ9-tetrahydrocannabinol (THC), cannabidiol 
(CBD), or a combination of the two between 2008 and 2019 in Switzerland. Out of 205 contacted families, 90 agreed to par-
ticipate. The median age at the first prescription was 11.5 years (interquartile range (IQR) 6–16), and 32 patients were female 
(36%). Fifty-one (57%) patients received CBD only and 39 (43%) THC. Patients were more likely to receive THC therapy 
if one of the following symptoms or signs were present: spasticity, pain, lack of weight gain, vomiting, or nausea, whereas 
seizures were the dominant indication for CBD therapy. Improvements were reported in 59 (66%) study participants. The 
largest treatment effects were reported for pain, spasticity, and frequency of seizures in participants treated with THC, and for 
those treated with pure CBD, the frequency of seizures. However, 43% of caregivers reported treatment interruptions, mainly 
because of lack of improvement (56%), side effects (46%), the need for a gastric tube (44%), and cost considerations (23%).
Conclusions: The effects of medical cannabis in children and adolescents with chronic conditions are unknown except for 
rare seizure disorders, but the caregiver-reported data analysed here may justify trials of medical cannabis with standardized 
concentrations of THC or CBD to assess its efficacy in the young.
What is Known:
• The use of medical cannabis (THC and CBD) to treat a variety of diseases among children and adolescents is increasing.
• In contrast to adults, there is no evidence to support the use of medical cannabis to treat chronic pain and spasticity in children, but substan-
tial evidence to support the use of CBD in children with rare seizure disorders.
What is New:
• This study provides important insights into prescription practices, dosages, and treatment outcomes in children and adolescents using medi-
cal cannabis data from a real-life setting.
• The effects of medical cannabis in children and adolescents with chronic conditions shown in our study support trials of medical cannabis 
for chronic conditions.
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Background
Cannabis sativa, commonly known as cannabis, contains 
more than 600 ingredients. Among them are more than 
100 phytocannabinoids, which include the substance 
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Δ9-tetrahydrocannabinol (THC) [1]. THC is best known 
for its psychotropic effect, but THC-containing prod-
ucts are also used to alleviate pain, spasticity, vomit-
ing, nausea, and loss of appetite. Drugs containing THC 
have been used to treat these symptoms in children with 
cancer, neurodegenerative diseases, cerebral palsy, trau-
matic brain injury, posttraumatic stress disorders, and 
Tourette syndrome [2–5]. In addition to THC, cannabis 
contains the phytocannabinoid cannabidiol (CBD), which 
has anti-inflammatory, antiepileptic, antipsychotic, and 
anxiety-relieving properties [6]. In children, CBD has 
been mainly used to treat epilepsy [2, 7–10], anxiety 
[11, 12], and autism [12, 13]. There is substantial evi-
dence to support the use of CBD in children with rare 
seizure disorders, but the evidence is lacking for other 
types of seizures and medical conditions [2, 7–10]. How-
ever, knowledge about the use and efficacy of medical 
cannabis is limited beyond these conditions. Therefore, 
this study provides important insights into prescription 
practices, dosages, and treatment outcomes in children 
and adolescents using medical cannabis data from a real-
life setting in Switzerland.
Synthetic or natural cannabis-containing preparations 
with more than 1% THC are regulated as narcotic drugs in 
Switzerland [14]. In 2011, a revision of the Swiss Law on 
Narcotics and Psychotropic Substances (Narcotics Law) 
authorized the Federal Office of Public Health to issue 
exceptional licenses for the medical use of substances 
containing more than 1% THC [15]. In contrast, pure 
CBD-containing preparations do not require exceptional 
authorizations for the prescription to patients [15, 16]. 
At present, several oral THC-containing preparations are 
prescribed as extemporaneous formulations in Switzer-
land with exceptional permission from the federal author-
ities. Until the end of April 2019, only two pharmacies 
(‘Bahnhof Apotheke Langnau AG’ and ‘Apotheke zur 
Eiche AG’) were authorized to produce THC-containing 
preparations for medical use.
In a previous study, we examined the requests for medi-
cal use of cannabinoids submitted to the Federal Office of 
Public Health in 2013 and 2014. We found that exceptional 
licenses for medical use of cannabinoids increased (from 
542 patients treated in 2013 to 825 in 2014), with 1193 
unique patients receiving treatment with cannabinoids 
[17]. Only 14 patients (1.2%) were younger than 20 years. 
Since then, the number of children and adolescents receiv-
ing medical cannabis has increased. Here, we examined the 
clinical and epidemiological characteristics of medical can-
nabis treatment and caregiver-reported effects in children 
and adolescents in Switzerland from February 2008 to June 
2019.
Methods
Study design and data collection
This is a retrospective observational study that collected data 
from patients’ families. We obtained a list of all children 
and adolescents under 18 years of age who received medical 
THC- or CBD-containing preparations between February 
2008 and June 2019 from the ‘Bahnhof Apotheke Langnau 
AG’ pharmacy in Langnau, Switzerland. The children and 
adolescents who received medical cannabis preparations 
from the pharmacy in Langnau came from all regions in 
Switzerland. The pharmacy in Langnau was one of two 
pharmacies in Switzerland authorized by the authorities 
to provide medical cannabis, as prescribed by the treat-
ing physician. The patient list included details on the date 
of birth, sex, medical diagnosis, date of prescriptions, 
the preparations including the concentration of CBD 
or THC, and the patients’ and the prescribing physicians’ 
contact details.
We developed and piloted a standardized question-
naire in collaboration with an advisory panel consist-
ing of two pharmacists and three clinicians with expe-
rience with medical cannabis. We piloted the German 
and French version of the questionnaire with caregivers 
for completeness and understandability. The question-
naire had three sections: (i) basic information such as 
sex, age, diagnosis, medications other than medical can-
nabis, and non-pharmacological therapies; (ii) details on 
the medical cannabis therapy, including the symptoms 
triggering therapy, type of medical cannabis, initial and 
current or last dosage, side effects, treatment interrup-
tions, and treatment effects; and (iii) costs of cannabis 
therapy, including coverage of the expenses by health 
insurance or out of pocket. An English translation of the 
questionnaire is reproduced in the supplemental informa-
tion (Table S1). We assessed treatment effects using a 
Likert scale with options ranging from ‘much less’, ‘less’, 
‘no change’, ‘more’, to ‘much more’. The survey was 
provided in paper form or electronically in a REDCap 
application [18].
We sent all children and adolescents’ caregivers 
an invitation letter with information on the study, the 
informed consent form, and the questionnaire with a pre-
paid return envelope. We sent non-responders another 
questionnaire 4–6 weeks later. In the event of continued 
nonresponse, we contacted families by phone. Depend-
ing on the caregivers’ preference, either a caregiver 
or the adolescent (≥ 14 years old) or both filled in the 
questionnaire.
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Definitions
We assigned children and adolescents to two groups: those 
treated with a pure CBD preparation and those treated with 
a THC-containing preparation (with or without low con-
centrations of CBD). Patients treated with both THC and 
pure CBD were analysed in the THC group. In other words, 
patients who received THC, and an additional preparation 
of pure CBD, were included in the THC group. The medical 
cannabis preparations were standardized for THC or CBD 
concentration. The pure THC solution (dronabinol solution 
2.5%) contained 0.7 mg THC per drop, the standardized 
alcohol-based cannabis tincture (10 mg THC/ml and 20 mg 
CBD/ml) 0.3 mg THC and 0.6 mg CBD per drop, and the 
standardized cannabis oil (10 mg THC/ml and 20 mg CBD/
ml) 0.4 mg THC and 0.8 mg CBD per drop. The pure CBD 
solutions with concentrations of 2.5%, 5%, and 10% con-
tained 0.7 mg, 1.4 mg, and 2.8 mg per drop, respectively 
[19, 20].
We categorized the diagnosis by the International Clas-
sification of Diseases (ICD-10), version 2019, into nine 
groups (ICD-10 codes in parentheses):
• Infectious and parasitic diseases (A00-B99).
• Cancer (C00–C97).
• Endocrine, nutritional, and metabolic diseases (E00-
E90).
• Mental and behavioural disorders (F00–F99).
• Diseases of the nervous system (G00–G99).
• Diseases of the skin and subcutaneous tissue (L00-
L99).
• Diseases of the musculoskeletal system and connective 
tissue (M00-M99).
• Congenital malformations, deformations, and chromo-
somal abnormalities (Q00-Q99).
• Injury, poisoning, and other conditions with external 
causes (S00–S99).
Statistical analysis
We used descriptive statistics to characterize patients and 
treatment effects and assessed differences between groups 
using chi‐square, Fisher’s exact, or Wilcoxon rank‐sum tests. 
We assessed changes in the dosage of products using the 
paired t-test. All analyses were done in Stata (version 15.1, 
College Station, TX, USA).
Ethics
The Cantonal Ethics Committee Bern, Switzerland, 
approved this study (No. 2019–00,049). Written informed 
consent was obtained from the caregivers of each child or 
adolescent younger than 14 years. Among older adolescents, 
either the adolescent or the caregivers gave informed 
consent.
Results
The patient list of the pharmacy included data on 205 chil-
dren or adolescents who were treated with THC- or CBD-
containing preparations between February 2008 and June 
2019. The first prescription to a child or adolescent was in 
2013. Initially, we received 77 responses from caregivers. 
After the reminders, 90 caregivers (43.9%) agreed to par-
ticipate in the study. Figure 1 shows the recruitment into 
the study. We compared the characteristics of the 90 par-
ticipating children or adolescents to the 115 patients who 
did not participate. There were no differences in age and 
the type of medical cannabis prescribed. Compared to non-
responders, participants were more likely to be male, to have 
more than one ICD-10 diagnosis, to have a disease of the 
nervous system or an endocrine, nutritional and metabolic 
disease, and have multiple prescriptions of medical cannabis 
products. According to the ICD-10 classification, the most 
common diseases among the 205 children or adolescents 
were diseases of the nervous system (120; 59%), mental and 
behavioural disorders (26; 13%), cancer (15; 7%), congeni-
tal malformations, deformations and chromosomal abnor-
malities (15; 7%), and endocrine, nutritional, and metabolic 
diseases (11; 5%). For 34 (17%), the diagnosis was missing 
(Table S2).
Patient characteristics
The median age at the first prescription of the 90 partici-
pants was 11.5 years (interquartile range 6–15), and 32 
were female (36%, Table 1). The youngest participant was 
4 months old with a neurodegenerative disease and the old-
est 17 years old with epilepsy. Both received CBD only to 
treat seizures. More than half of the participants (57%) suf-
fered from more than one disease. The most common diag-
nosis were epilepsy (66; 73%), cerebral palsy (32; 36%), 
encephalopathy (15; 17%), metabolic diseases (8; 9%), and 
autism (7; 7%). Among the 66 participants with epilepsy, 
24 (36%) had only epilepsy, whereas 42 (64%) had epilepsy 
with additional diseases (Table S3).
Fifty-one participants (57%) were treated with CBD 
only and 39 (43%) with a THC preparation. Six patients 
who received a THC-containing preparation and pure CBD 
(three received dronabinol and 2.5%, 5%, or 10% pure 
CBD; two cannabis tincture and 5% or 10% pure CBD; and 
one cannabis oil and 2.5% CBD) were included in the THC 
group. When analysing the groups ‘THC only’ and ‘THC 
and CBD’, we found no statistical difference (Table S4). 
THC was more commonly prescribed to participants with 
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cancer (p = 0.03), whereas CBD only was more frequently 
prescribed to participants with epilepsy (p < 0.001). Par-
ticipants were more likely to receive THC therapy if one 
of the following symptoms or signs were present: spastic-
ity, pain, lack of weight gain, loss of appetite, vomiting, 
or nausea, whereas seizures were the dominant indication 
for CBD only therapy. The daily dosage of medical can-
nabis preparations increased over time for both THC- and 
CBD-only preparations (Fig. 2).
The majority of participants (72; 80%) received at least 
one concomitant medication. The most frequent medica-
tion categories were antiepileptic drugs (60; 67%), fol-
lowed by muscle relaxants (10; 11%), analgesics (10; 
11%), and other drugs (25; 28%). Also, 63 (70%) partici-
pants received physical therapy, 46 (51%) occupational 
therapy, and 23 (26%) osteopathy (Table 1).
Treatment interruption and side effects
During medical cannabis treatment, 39 of the 90 participants 
(43%) reported a treatment interruption (Tables 2 and S5). 
Twenty-two stopped treatment definitively, and 17 resumed 
treatment (six continued with the same preparation and dos-
age, seven continued with the same preparation but a differ-
ent dosage, four continued with another preparation). The 
median time from treatment initiation to treatment interrup-
tion was eight weeks (IQR 3–32 weeks). The reasons given 
for the treatment interruption included lack of improvement 
in 22 patients (56%), side effects in 18 (46%), the need for 
a gastric tube in 17 cases (44%) preventing the continua-
tion of treatment, and cost considerations in 9 patients (23%, 
Tables 2 and S5). Side effects were observed in 25 of the 
90 participants (28%) and similar in the THC and CBD 
Fig. 1  Flow of inclusion of 
study participants
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Table 1  Characteristics of the 
90 included participants
Total THCa CBD only p value
Total n = 90 (100%) n = 39 (100%) n = 51 (100%)
Sex 0.62
Male 58 (64) 24 (62) 34 (67)
Female 32 (36) 15 (38) 17 (33)
Median age at the first prescription in years (IQR) 11.5 (6–15) 14 (9–16) 9 (6–14) 0.029
Number of diagnoses 0.09
One 39 (43) 13 (33) 26 (51)
Two or more 51 (57) 26 (67) 25 (49)
Diagnosisb
Epilepsy 66 (73) 22 (56) 44 (86) 0.001
  Drug-resistant epilepsy     20 (22) 3 (8) 17 (33)
  Dravet syndrome  7 (8) 1 (3) 6 (12)
  Lennox–Gastaut syndrome (LGS) 7 (8) - 7 (14)
  Absences 4 (4) 3 (8) 1 (2)
Cerebral palsy 32 (36) 19 (49) 13 (26) 0.071
Encephalopathy 15 (17) 6 (15) 9 (18) 0.78
Metabolic disease 8 (9) 6 (15) 2 (4) 0.07
Autism 7 (8) 1 (3) 6 (12) 0.13
Genetic disorder 6 (7) 4 (10) 2 (4) 0.40
Cancer 4 (4) 4 (10) 0 0.03
Tourette’s syndrome 3 (3) 2 (5) 1 (2) 0.58
Severe head injury 3 (3) 3 (8) 0 -
Otherc 8 (9) 4 (10) 4 (8)
Symptoms/indicationb
Seizure/epilepsy 60 (67) 20 (51) 40 (78) 0.007
Spasticity 27 (30) 20 (51) 7 (14) 0.001
Pain 26 (29) 20 (51) 6 (12) 0.001
Sleep disorder 15 (17) 5 (13) 10 (20) 0.39
Lack of weight gain 11 (12) 8 (21) 3 (6) 0.05
Anxiety disorders/behaviour 10 (11) 7 (18) 3 (6) 0.10
Vomiting 9 (10) 7 (18) 2 (4) 0.04
Nausea 8 (9) 7 (18) 1 (2) 0.02
Loss of appetite 7 (8) 6 (15) 1 (2) 0.04
ADHD, behaviour change 5 (6) 1 (3) 4 (8) 0.38
Inflammatory condition 4 (4) 2 (5) 2 (4) 1.0
Tics 3 (3) 2 (5) 1 (2) 0.58
Others 3 (3) 3 (8) - -
Type of medical cannabis preparation, initial -
THC-based preparation 39 (43) 39 (100)
  Dronabinol solution 2.5% 20 (22) 20 (51) -
  Standardized cannabis tincture 10 (11) 10 (26) -
  Standardized cannabis oil 9 (10) 9 (23) -
CBD-based preparation 51 (57) 51 (100)
  CBD 2.5% 20 (22) - 20 (39)
  CBD 5% 17 (19) - 17 (33)
  CBD 10% 14 (16) - 14 (28)
Other co-medicationsb
Antiepileptic drugs 60 (67) 21 (5) 39 (77) 0.024
Muscle relaxants 10 (11) 8 (21) 2 4) 0.018
Analgesics and opiates 10 (11) 9 (23) 1 (2) 0.002
Other drugs 25 (28) 15 (39) 11 (22) 0.08
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group. The three most common side effects were tiredness, 
sedation, and dry mouth (Tables 2 and S5).
Awareness, prescription, and cost modalities
Caregivers learned about medical cannabis therapy through 
the media (44; 49%), their family doctor or medical special-
ist (37; 41%), and friends or family members (21; 23%). 
In most cases (82; 91%), specialist doctors, neuropaediatri-
cians, neurologists, oncologists, or palliative care specialists 
prescribed the preparation. The cost of the first prescription 
was reimbursed by the invalidity insurance (insurance cover-
ing some chronic diseases such as epilepsy or cerebral palsy) 
in 50 participants (56%), and the health insurance covered 
the cost for ten patients (11%, Table 3). For 27 participants 
(30%), caregivers paid out of their pocket. This situation 
persisted during the treatment. The monthly cost was below 
300 USD for 24 participants (27%), between 301 to 600 
USD for 22 (24%), more than 600 USD for 25 (28%). The 
cost was unknown for the remaining 19 children or adoles-
cents. Many caregivers were concerned about the high cost 
of medical cannabis preparations. Table S3 gives further 
details about costs.
Treatment effects of medical cannabis preparations
In 59 of 90 participants (66%), the treatment with medical 
cannabis was reported to be successful by the caregivers 
(Tables 2 and S5). Participants treated with THC prod- 
ucts most frequently reported a reduction of pain, spasticity, 
seizures, and a reduction in the number of drugs taken. 
Participants treated with pure CBD-containing products 
most commonly reported a reduction in the frequency of 
seizures. Irrespective of treatment with THC or CBD only, 
caregivers felt that their children or adolescents were more 
relaxed, more satisfied, and in better general condition than 
before the therapy with medical cannabis (Fig. 3, Table S6). 
The use of other therapies like physiotherapy, osteopathy, 
speech, or occupational therapy did not change, regardless 
of whether the patients received THC or CBD only (Fig. 3).
Discussion
The use of medical cannabis to treat a variety of diseases 
among children and adolescents is increasing. We found 
that THC was most frequently used to treat pain, spasticity, 
seizures, lack of weight gain, and nausea, while CBD only 
was used to treat pain, seizures, and sleep disorders. The 
largest treatment effects were reported for pain, spasticity, 
and frequency of seizure in participants treated with THC, 
and for those treated with CBD only, the frequency of sei-
zures. Irrespective of treatment with THC or CBD only, or 
a preparation containing both, most caregivers felt that their 
children and adolescents were more relaxed, more satisfied, 
and had increased quality of life with medical cannabis treat-
ment. The treatment was reported to be successful in two 
thirds of participants. Treatment interruption was frequent, 
mainly due to lack of improvement, side effects, or cost 
considerations.
CBD cannabidiol, THC tetrahydrocannabinol, ADHD attention-deficit/hyperactivity disorder
a Six patients who received both THC and pure CBD were assigned to THC
b p values for each diagnosis vs. no disease (reference), each symptom vs. no symptom (reference), and each 
additional therapy vs. no additional therapy (reference), each co-medication vs. no other co-medication 
were calculated using chi-squared of Fisher exact
c Other diseases include 2 with neuropathic pain, 2 with AD(H)S, 2 with epidermolysis sclerosis, 1 with 
depression, 1 with tuberous sclerosis
Table 1  (continued) Total THCa CBD only p value
Total n = 90 (100%) n = 39 (100%) n = 51 (100%)
Additional therapyb
Physical therapy 63 (70) 30 (77) 33 (65) 0.21
Occupational therapy 46 (51) 17 (44) 29 (57) 0.21
Osteopathy 23 (26) 10 (26) 13 (26) 0.99
Speech therapy 9 (10) 4 (10) 5 (10) 0.94
Traditional Chinese Medicine (TCM) 6 (7) 2 (5) 4 (8) 0.61
Homeopathy 5 (6) 2 (5) 3 (6) 0.88
Chiropractic 5 (6) 2 (5) 3 (6) 0.88
Others 11 (12) 5 (13) 6 (12) 0.88
No answer 13 (14) 5 (13) 8 (16) 0.90
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In our study, 80% of participants suffered from a disease 
of the nervous system. The most common diagnosis was 
epilepsy, for which 55% of caregivers reported a reduction in 
seizures and 6% reported seizure aggravation while on medi-
cal cannabis. In a similar study examining treatment with 
cannabidiol-enriched cannabis in children with treatment-
resistant epilepsy, 84% of caregivers reported a reduction in 
the frequency of their children’s seizures [21]. Another ret-
rospective study based on clinical records showed that chil-
dren with intractable epilepsy treated with CBD-enriched 
cannabis oil with a 20:1 CBD to THC formulation reported 
a reduction in the frequency of seizure in almost 90% of 
children, along with aggravation of seizures in 7% [22]. 
Beyond observational studies, randomized controlled trials 
(RCT) were conducted in children with treatment-resistant 
epilepsy to assess the efficacy and tolerability of CBD com-
pared to placebo. These studies confirmed that CBD reduces 
seizure frequency [7–10]. A study from Israel showed that 
epilepsy in children can also be treated with a standard-
ized preparation containing CBD and THC [23]. Finally, 
a recent systematic review and meta-analysis summarized 
results from intervention studies and concluded that CBD is 
more effective than placebo for treatment-resistant epilepsy, 
regardless of the aetiology of the epileptic syndrome [24].
Fig. 2  Changes of the pre-
scribed medical cannabis prepa-
ration from initial to current 
dosage by patients for whom 
initial and current dosage was 
available
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The second most common indication for the use of 
medical cannabis was spasticity. Among our participants, 
49%, mainly those with cerebral palsy, reported a reduc-
tion of spasticity. A case series of 16 children, adolescents 
or young adults with resistant spasticity in palliative care 
who received 2.5% dronabinol showed reduced spasticity 
[25]. An intervention study in children with complex motor 
disorders treated either with cannabis oil with a 20:1 or 6:1 
CBD to THC formulation showed similar improvements in 
both groups in spasticity, sleep difficulties, pain severity, 
and quality of life [26]. However, a recent multicentre RCT 
(2020) in 72 children or adolescents with cerebral palsy or 
another central nervous system injury after birth found no 
significant difference in spasticity with a cannabis extract 
(Nabiximols) and placebo after 12 weeks of treatment (3). 
Today, the evidence that medical cannabis has an impact 
on spasticity in children is weak. In adults with multiple 
sclerosis or paraplegia, a systematic review of RCTs showed 
some evidence supporting the efficacy of medical cannabis 
in spasticity [27–30].
he use of medical cannabis in children and adolescents 
poses risks. Our study found that medical cannabis was 
prescribed for various conditions, even though the evi-
dence is weak for many. Although there is some evidence 
in adults supporting the efficacy of medical cannabis for 
some diseases, we should not extrapolate results from 
adults to children. Limited evidence exists for the effec-
tive use of different cannabis derivatives, dosage, and 
Table 2  Outcomes of medical 
cannabis therapy among 90 
children and adolescents
CBD cannabidiol, THC tetrahydrocannabinol
a Six patients who received both THC and pure CBD were assigned to THC
b p values for each reason for interruption vs. no interruption (reference)
Total
n = 90 (100%)
THCa
n = 39 (100%)
CBD only
n = 51 (100%)
p value
Treatment success (caregiver perspective) 0.65
Yes 59 (66) 26 (67) 33 (65)
No 28 (31) 11 (28) 17 (33)
Missing 3 (3) 2 (5) 1 (2)
Treatment interruptions/treatment stop 0.70
Yes 39 (43) 16 (41) 23 (45)
No 51 (57) 23 (59) 28 (55)
Median time to first interruption/treat-
ment stop in weeks (IQR)
8 (3–32) 6.5 (3.5–36) 8 (3–20)
  Number of observations 25 8 17
Reasons for interruptionb
No improvement and stopped treatment 22 (24) 9 (23) 13 (26) 0.79
Side effects 18 (20) 8 (21) 10 (20) 0.92
Taking preparation via the tube 17 (19) 7 (18) 10 (20) 0.84
Costs 9 (10) 0 9 (18) 0.004
Unpleasant smell/taste 4 (4) 2 (5) 2 (4) 1
Side effects 0.94
No 65 (72) 28 (72) 37 (73)
Yes 25 (28) 11 (28) 14 (27)
  Tiredness 11 (12) 6 (15) 5 (10)
  Sedation 7 (8) 4 (10) 3 (6)
  Dry mouth 5 (6) 2 (5) 3 (6)
  Nausea and vomiting 4 (4) 2 (5) 2 (4)
  Dizziness 2 (2) 2 (5) 0
  Hallucinations 2 (2) 1 (3) 1 (2)
  Impaired ability to think (cognitive 
changes)
2 (2) 2 (5) 0
  Changed movement behaviour 2 (2) 1 (3) 1 (2)
  Diarrhoea 2 (2) 0 2 (4)
  Red eyes 1 (1) 1 (3) 0
  Others 6 (7) 0 6 (12)
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indications. Indeed, the high rate of treatment interrup-
tion or stop (43%) seen in our study was driven by side 
effects and lack of improvement. Thus, clinicians should 
closely monitor children and adolescents on medical can-
nabis for efficacy and adverse effects, and they should be 
experienced in the treatment of the underlying disease. In 
addition, potential drug interactions should be considered. 
A systematic review on safety and efficacy in epilepsy sum-
marized drug–drug interactions of CBD with other drugs 
metabolized in the liver by cytochrome P450 enzymes 
exists. Therefore, treatment with CBD can result in ele-
vated liver enzyme, especially when co-medicated with 
the antiepileptic drug valproate [31]. However, current 
evidence is limited about both the interaction of medical 
cannabis with other drugs. Treatment guidelines are needed 
to inform decision making by clinicians and caregivers. 
Although such guidelines are available in a few countries 
[32–34], they currently do not exist in Switzerland and 
many other countries. Another reason for stopping treat-
ment was the costs for medical cannabis, which have to 
be paid out of the caregivers’ pocket. The production of 
quality-controlled medical cannabis is laborious. The costs 
for other medical and nonmedical treatments in these chil-
dren, which will generally be covered by health insurance, 
might be substantially higher [35].
This is one of the first studies reporting on prescription 
practices, dosages, and treatment outcomes in a large 
sample of children and adolescents using medical canna- 
bis in a real-life setting. Two strengths particularly dis-
tinguish our study from others. Participants were patients 
under 18 years of age who received medical cannabis over 
the entire period since its use was authorised in Switzerland. 
The pharmacy in Langnau is a pioneer in this field and the 
largest professional distributor of medical cannabis in Swit- 
zerland. Also, even though the dosage of medical cannabis 
preparations varied, the concentrations were standardized. 
Other publications and recommendations often lack such 
standardization, which hampers comparisons across 
studies.
The most important limitation of our study was the lack 
of a comparison group. Another limitation derives from the 
fact that the caregivers reported the data, which may lead to 
a recall bias. However, it is common in the paediatric field 
to collect outcome data reported by caregivers, especially in 
children with disabilities. A further limitation is the potential 
selection bias arising from group differences between those 
who participated and those who did not. Participants’ health 
and the situations of participating families may have been 
better than those of nonparticipants. How this could have 
influenced our findings is unknown.
Table 3  Sources of coverage of 
medical cannabis in USD
CBD cannabidiol, THC tetrahydrocannabinol
a Six patients who received both THC and pure CBD were assigned to THC
Total
n = 90 (100%)
THCa
n = 39 (100%)
CBD only
n = 51 (100%)
p value
Initial cost coverage 0.17
Invalidity Insurance 50 (56) 22 (56) 28 (55)
Out of pocket 27 (30) 8 (21) 19 (37)
Health insurance 10 (11) 8 (21) 2 (4)
Other (support-group) 1 (1) 0 1 (2)
Unknown 2 (2) 1 (3) 1 (2)
Current cost coverage
Invalidity Insurance 54 (60) 24 (62) 30 (59) 0.26
Out of pocket 24 (27) 7 (20) 17 (33)
Health insurance 9 (10) 7 (20) 2 (4)
Other (support-group) 1 (1) 0 1 (2)
Unknown 2 (2) 1 (3) 1 (2)
Exact monthly amount, 
median (IQR)
360 (212–1250) 250 (140–1250) 500 (250–1400) 0.49
  Number of observations 33 11 22
Monthly costs 0.051
 < 100 USD 4 (4) 3 (8) 1 (2)
100–300 USD 20 (22) 8 (21) 12 (26)
301–600 USD 22 (24) 8 (21) 14 (27)
 > 600 USD 25 (28) 7 (18) 18 (35)
Unknown 19 (21) 13 (33) 6 (12)
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Fig. 3  Reported treatment effects of medical cannabis use in children and adolescents from the caregivers’ perspective. The number indicates the 
number of responses. Detailed results are presented in additional Table 3
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Conclusions
In Switzerland, medical cannabis was mainly prescribed to 
children and adolescents with neurological diagnoses, par-
ticularly epilepsy. Although evidence supporting efficacy is 
lacking, medical cannabis was prescribed to children and 
adolescents for various other conditions. For two thirds of 
participants treated with standardized THC or CBD prepara-
tions, the caregiver reported an improvement in their condi-
tion and well-being. Others stopped preparations because 
of lack of effectiveness or side effects. Medical cannabis 
could be a promising and useful therapy for children and 
adolescents with neurological conditions. However, we need 
further RCTs with standardized THC and CBD preparations 
to assess the efficacy of medical cannabis in different dis-
eases and long-term effects in the young.
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